AC Im­mune has 're­mark­able' Alzheimer's vac­cine da­ta. Just don't ask to see them

AC Im­mune an­nounced it has “re­mark­able,” “un­prece­dent­ed” re­sults on an Alzheimer’s vac­cine. You’re just not al­lowed to see the da­ta.

On Thurs­day, the J&J-part­nered Swiss biotech said that its vac­cine had gen­er­at­ed “high” lev­els of an­ti­bod­ies against tau, a tan­gled pro­tein com­mon­ly im­pli­cat­ed in Alzheimer’s, in every pa­tient in their Phase I/II tri­al for the neu­rode­gen­er­a­tive dis­ease. The stock $ACIU in­stant­ly dou­bled in pre-mar­ket trad­ing, ris­ing from $7.30 to $14.70, and briefly mak­ing AC Im­mune once again a $1 bil­lion com­pa­ny.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER